Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105

Cancer Immunology, Immunotherapy

Volumn 60, Issue 7, 2011, Pages 931-942

  Wood, Laurence M ^a   Pan, Zhen Kun ^a   Guirnalda, Patrick ^a   Tsai, Peter ^a   Seavey, Matthew ^a,b   Paterson, Yvonne ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CEPHALON INC   (United States)

Author keywords

Breast cancer; CD105; Endoglin; Listeria monocytogenes; Vaccine; Vasculature

Indexed keywords

CANCER VACCINE; CD31 ANTIGEN; ENDOGLIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; LISTERIOLYSIN O; LIVE VACCINE; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; HYDROPHOBICITY; IN VIVO STUDY; LISTERIA MONOCYTOGENES; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; CANCER VACCINES; FEMALE; HUMANS; IMMUNOTHERAPY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LISTERIA; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; RATS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SURVIVAL RATE;

EID: 79959746709     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1002-x     Document Type: Article

References (55)

1. GH Algire HW Chalkley FY Legallais HD Park 1945 Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants J Natl Cancer Inst 11 3 555 580
2. JS Youngner GH Algire 1949 The effect of vascular occlusion on transplanted tumors J Natl Cancer Inst 10 3 565 579 15403011 1:STN:280:DyaG3c%2Fht1KnsQ%3D%3D
3. J Folkman 1971 Tumor angiogenesis: therapeutic implications N Engl J Med 285 21 1182 1186 4938153 10.1056/NEJM197111182852108 1:STN:280: DyaE38%2FgvVCqsQ%3D%3D
4. J Folkman E Merler C Abernathy G Williams 1971 Isolation of a tumor factor responsible for angiogenesis J Exp Med 133 2 275 288 4332371 10.1084/jem.133.2.275 1:STN:280:DyaE38%2Fot1SgsA%3D%3D
5. New treatments for colorectal cancer (2004) FDA Consum 38(3):17
6. MM Seavey PC Maciag N Al-Rawi D Sewell Y Paterson 2009 An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu + breast tumors in a mouse model J Immunol 182 9 5537 5546 19380802 10.4049/jimmunol.0803742 1:CAS:528:DC%2BD1MXkslKiuro%3D
7. PC Maciag MM Seavey ZK Pan S Ferrone Y Paterson 2008 Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature Cancer Res 68 19 8066 8075 18829565 10.1158/0008-5472.CAN-08-0287 1:CAS:528:DC%2BD1cXhtF2msLvN
8. AG Niethammer R Xiang JC Becker H Wodrich U Pertl G Karsten, et al. 2002 A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth Nat Med 8 12 1369 1375 12415261 10.1038/nm1202-794 1:CAS:528:DC%2BD38XptVSgsbo%3D (Pubitemid 36019421)
9. N Mizutani Y Luo M Mizutani RA Reisfeld R Xiang 2004 DNA vaccines suppress angiogenesis and protect against growth of breast cancer metastases Breast Dis 20 81 91 15687710 1:CAS:528:DC%2BD2cXhtVahsLjL (Pubitemid 39600449)
10. SH Lee N Mizutani M Mizutani Y Luo H Zhou C Kaplan, et al. 2006 Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer Cancer Immunol Immunother 55 12 1565 1574 16565828 10.1007/s00262-006-0155-5 1:CAS:528:DC%2BD28XptVWqtro%3D (Pubitemid 44327844)
11. P Lastres A Letamendia H Zhang C Rius N Almendro U Raab, et al. 1996 Endoglin modulates cellular responses to TGF-beta 1 J Cell Biol 133 5 1109 1121 8655583 10.1083/jcb.133.5.1109 1:CAS:528:DyaK28XjsVWhtr4%3D (Pubitemid 26172515)
12. DY Li LK Sorensen BS Brooke LD Urness EC Davis DG Taylor, et al. 1999 Defective angiogenesis in mice lacking endoglin Science 284 5419 1534 1537 10348742 10.1126/science.284.5419.1534 1:CAS:528:DyaK1MXjs1WhsrY%3D (Pubitemid 29291401)
13. A Bourdeau ME Faughnan M Letarte 2000 Endoglin-deficient mice, a unique model to study hereditary hemorrhagic telangiectasia Trends Cardiovasc Med 10 7 279 285 11343967 10.1016/S1050-1738(01)00062-7 1:CAS:528:DC%2BD3MXjtlegt7Y%3D (Pubitemid 32422105)
14. C Li IN Hampson L Hampson P Kumar C Bernabeu S Kumar 2000 CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells FASEB J 14 1 55 64 10627280 1:CAS:528:DC%2BD3cXltFKnsw%3D%3D (Pubitemid 30051523)
15. C Li B Guo C Bernabeu S Kumar 2001 Angiogenesis in breast cancer: the role of transforming growth factor beta and CD105 Microsc Res Tech 52 4 437 449 11170303 10.1002/1097-0029(20010215)52:4<437::AID-JEMT1029>3.0.CO;2-G 1:CAS:528:DC%2BD3MXhsl2jtro%3D (Pubitemid 32167832)
16. S Cheifetz T Bellon C Cales S Vera C Bernabeu J Massague, et al. 1992 Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells J Biol Chem 267 27 19027 19030 1326540 1:CAS:528:DyaK38Xlt1Ggurg%3D
17. J Mokrosinski WM Krajewska 2008 TGF beta signalling accessory receptors Postepy Biochem 54 3 264 273 19112825 1:CAS:528:DC%2BD1MXhsVemsr3I
18. C Bernabeu JM Lopez-Novoa M Quintanilla 2009 The emerging role of TGF-beta superfamily coreceptors in cancer Biochim Biophys Acta 1792 10 954 973 19607914 1:CAS:528:DC%2BD1MXhtF2jsrrJ
19. T Sanchez-Elsner LM Botella B Velasco C Langa C Bernabeu 2002 Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways J Biol Chem 277 46 43799 43808 12228247 10.1074/jbc.M207160200 1:CAS:528:DC%2BD38Xos1alu7s%3D (Pubitemid 36157800)
20. LK Sorensen BS Brooke DY Li LD Urness 2003 Loss of distinct arterial and venous boundaries in mice lacking endoglin, a vascular-specific TGFbeta coreceptor Dev Biol 261 1 235 250 12941632 10.1016/S0012-1606(03)00158-1 1:CAS:528:DC%2BD3sXmslegt7w%3D (Pubitemid 36993829)
21. HM Arthur J Ure AJ Smith G Renforth DI Wilson E Torsney, et al. 2000 Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development Dev Biol 217 1 42 53 10625534 10.1006/dbio.1999.9534 1:CAS:528:DC%2BD3cXhs1Wlug%3D%3D (Pubitemid 30046798)
22. Pardali E, van der Schaft DW, Wiercinska E, Gorter A, Hogendoorn PC, Griffioen AW et al (2011) Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma. Oncogene 30(3):334-345
23. A Duwel N Eleno M Jerkic M Arevalo JP Bolanos C Bernabeu, et al. 2007 Reduced tumor growth and angiogenesis in endoglin-haploinsufficient mice Tumour Biol 28 1 1 8 17108712 (Pubitemid 46012460)
24. E Perez-Gomez N Eleno JM Lopez-Novoa JR Ramirez B Velasco M Letarte, et al. 2005 Characterization of murine S-endoglin isoform and its effects on tumor development Oncogene 24 27 4450 4461 15806144 10.1038/sj.onc.1208644 1:CAS:528:DC%2BD2MXlsVWmt7c%3D (Pubitemid 40961768)
25. E Perez-Gomez M Villa-Morales J Santos J Fernandez-Piqueras C Gamallo J Dotor, et al. 2007 A role for endoglin as a suppressor of malignancy during mouse skin carcinogenesis Cancer Res 67 21 10268 10277 17974968 10.1158/0008-5472.CAN-07-1348 1:CAS:528:DC%2BD2sXht1erur%2FF (Pubitemid 350070800)
26. Chung AS, Lee J, Ferrara N (2010) Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 10(7):505-514
27. C Li B Guo PB Wilson A Stewart G Byrne N Bundred, et al. 2000 Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer Int J Cancer 89 2 122 126 10754488 10.1002/(SICI)1097-0215(20000320)89: 2<122::AID-IJC4>3.0.CO;2-M 1:CAS:528:DC%2BD3cXislehsro%3D (Pubitemid 30185919)
28. N Takahashi R Kawanishi-Tabata A Haba M Tabata Y Haruta H Tsai, et al. 2001 Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin Clin Cancer Res 7 3 524 532 11297243 1:CAS:528: DC%2BD3MXjtVOgur4%3D (Pubitemid 32707974)
29. JM Wang S Kumar D Pye AJ van Agthoven J Krupinski RD Hunter 1993 A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues Int J Cancer 54 3 363 370 8509210 10.1002/ijc.2910540303 1:STN:280:DyaK3s3osFygug%3D%3D (Pubitemid 23169671)
30. JM Wang S Kumar D Pye N Haboubi L al-Nakib 1994 Breast carcinoma: comparative study of tumor vasculature using two endothelial cell markers J Natl Cancer Inst 86 5 386 388 7508519 10.1093/jnci/86.5.386 1:STN:280: DyaK2c7ktF2luw%3D%3D (Pubitemid 24076881)
31. FJ Burrows EJ Derbyshire PL Tazzari P Amlot AF Gazdar SW King, et al. 1995 Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy Clin Cancer Res 1 12 1623 1634 9815965 1:CAS:528:DyaK28XmvVWgsg%3D%3D (Pubitemid 26030991)
32. M Tabata M Kondo Y Haruta BK Seon 1999 Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using (125)I-labeled anti-endoglin monoclonal antibodies Int J Cancer 82 5 737 742 10417773 10.1002/(SICI)1097-0215(19990827) 82:5<737::AID-IJC18>3.0.CO;2-8 1:CAS:528:DyaK1MXltFOitLg%3D (Pubitemid 29356974)
33. J Benitez JM Ferreras R Munoz Y Arias R Iglesias M Cordoba-Diaz, et al. 2005 Cytotoxicity of an ebulin l-anti-human CD105 immunotoxin on mouse fibroblasts (L929) and rat myoblasts (L6E9) cells expressing human CD105 Med Chem 1 1 65 70 16789887 10.2174/1573406053402479 1:CAS:528:DC%2BD2MXhsVWkur4%3D
34. F Matsuno Y Haruta M Kondo H Tsai M Barcos BK Seon 1999 Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies Clin Cancer Res 5 2 371 382 10037187 1:CAS:528:DyaK1MXhsVWrtL4%3D (Pubitemid 29085191)
35. CT Guy MA Webster M Schaller TJ Parsons RD Cardiff WJ Muller 1992 Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease Proc Natl Acad Sci USA 89 22 10578 10582 1359541 10.1073/pnas.89.22.10578 1:CAS:528:DyaK3sXjs1ymsw%3D%3D
36. RT Reilly MB Gottlieb AM Ercolini JP Machiels CE Kane FI Okoye, et al. 2000 HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice Cancer Res 60 13 3569 3576 10910070 1:CAS:528:DC%2BD3cXkvFChsb8%3D (Pubitemid 30482178)
37. CJ Aslakson FR Miller 1992 Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor Cancer Res 52 6 1399 1405 1540948 1:STN:280:DyaK387nsVWmsA%3D%3D
38. K Tao M Fang J Alroy GG Sahagian 2008 Imagable 4T1 model for the study of late stage breast cancer BMC Cancer 8 228 18691423 10.1186/1471-2407-8-228
39. R Singh Y Paterson 2007 In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines Cancer Immunol Immunother 56 6 927 938 17131121 10.1007/s00262-006-0237-4 1:CAS:528:DC%2BD2sXjsFyhtbc%3D (Pubitemid 46723584)
40. WJ Muller 1991 Expression of activated oncogenes in the murine mammary gland: transgenic models for human breast cancer Cancer Metastasis Rev 10 3 217 227 1662559 10.1007/BF00050793 1:STN:280:DyaK387htVyqsw%3D%3D
41. Y Paterson PC Maciag 2005 Listeria-based vaccines for cancer treatment Curr Opin Mol Ther 7 5 454 460 16248280 1:CAS:528:DC%2BD2MXhtFyhtbjF (Pubitemid 41489186)
42. SH Kim F Castro Y Paterson C Gravekamp 2009 High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action Cancer Res 69 14 5860 5866 19584282 10.1158/0008-5472.CAN-08-4855 1:CAS:528:DC%2BD1MXosV2msbs%3D
43. AY Huang PH Gulden AS Woods MC Thomas CD Tong W Wang, et al. 1996 The immunodominant major histocompatibility complex class I- restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product Proc Natl Acad Sci USA 93 18 9730 9735 8790399 10.1073/pnas.93.18.9730 1:CAS:528:DyaK28XlsFehsL8%3D (Pubitemid 26296677)
44. SM Albelda WA Muller CA Buck PJ Newman 1991 Molecular and cellular properties of PECAM-1 (endoCAM/CD31): a novel vascular cell-cell adhesion molecule J Cell Biol 114 5 1059 1068 1874786 10.1083/jcb.114.5.1059 1:CAS:528:DyaK3MXltFWnsb4%3D (Pubitemid 21909867)
45. DW Miller W Graulich B Karges S Stahl M Ernst A Ramaswamy, et al. 1999 Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells Int J Cancer 81 4 568 572 10225446 10.1002/(SICI)1097-0215(19990517)81:4<568::AID-IJC11>3.0. CO;2-X 1:STN:280:DyaK1M3jvF2msA%3D%3D (Pubitemid 29203054)
46. E Fonsatti AP Jekunen KJ Kairemo S Coral M Snellman MR Nicotra, et al. 2000 Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model Clin Cancer Res 6 5 2037 2043 10815930 1:CAS:528:DC%2BD3cXktVWitr0%3D (Pubitemid 30305103)
47. Abe F, Dafferner AJ, Donkor M, Westphal SN, Scholar EM, Solheim JC et al (2010) Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice. Cancer Immunol Immunother 59(1):47-62
48. MK Donkor E Lahue TA Hoke LR Shafer U Coskun JC Solheim, et al. 2009 Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells Int Immunopharmacol 9 7-8 937 948 19362167 10.1016/j.intimp.2009.03.021 1:CAS:528:DC%2BD1MXms1Ors7w%3D
49. NC Souders DA Sewell ZK Pan SF Hussain A Rodriguez A Wallecha, et al. 2007 Listeria-based vaccines can overcome tolerance by expanding low avidity CD8 + T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer Cancer Immun 7 2 17279610
50. T Kamba BY Tam H Hashizume A Haskell B Sennino MR Mancuso, et al. 2006 VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature Am J Physiol Heart Circ Physiol 290 2 H560 H576 16172168 10.1152/ajpheart.00133.2005 1:CAS:528:DC%2BD28XhsFKjuro%3D
51. T Kamba DM McDonald 2007 Mechanisms of adverse effects of anti-VEGF therapy for cancer Br J Cancer 96 12 1788 1795 17519900 10.1038/sj.bjc.6603813 1:CAS:528:DC%2BD2sXmtlyqur4%3D (Pubitemid 46912024)
52. Y Cao 2009 Tumor angiogenesis and molecular targets for therapy Front Biosci 14 3962 3973 19273326 10.2741/3504 1:CAS:528:DC%2BD1MXltlWku7w%3D
53. K Shiozaki N Harada WR Greco A Haba S Uneda H Tsai, et al. 2006 Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin Cancer Immunol Immunother 55 2 140 150 15856228 10.1007/s00262-005-0691-4 1:CAS:528: DC%2BD2MXht1GlsLnN (Pubitemid 41682586)
54. C Peters X Peng D Douven ZK Pan Y Paterson 2003 The induction of HIV Gag-specific CD8 + T cells in the spleen and gut-associated lymphoid tissue by parenteral or mucosal immunization with recombinant Listeria monocytogenes HIV Gag J Immunol 170 10 5176 5187 12734365 1:CAS:528:DC%2BD3sXjsVGqsbg%3D (Pubitemid 36554750)
55. PC Maciag S Radulovic J Rothman 2009 The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix Vaccine 27 30 3975 3983 19389451 10.1016/j.vaccine.2009.04.041 1:CAS:528:DC%2BD1MXmvFGitLk%3D